European biotech’s reliance on later-stage US capital means that “European VCs’ role is to catalyze that US interest and form substantial funding syndicates,” says Sander Slootweg, co-owner and managing partner at Naarden, Netherlands-based @ForbionLifeSci
RT @NatureBiotech: European biotech companies raised unprecedented amounts of capital in 2019. Our April Feature looked at Europe’s biotech…
RT @NatureBiotech: European biotech companies raised unprecedented amounts of capital in 2019. Our April Feature looked at Europe’s biotech…
RT @NatureBiotech: European biotech companies raised unprecedented amounts of capital in 2019. Our April Feature looked at Europe’s biotech…
RT @NatureBiotech: European biotech companies raised unprecedented amounts of capital in 2019. Our April Feature looked at Europe’s biotech…
RT @NatureBiotech: European biotech companies raised unprecedented amounts of capital in 2019. Our April Feature looked at Europe’s biotech…
RT @NatureBiotech: European biotech companies raised unprecedented amounts of capital in 2019. Our April Feature looked at Europe’s biotech…
European biotech companies raised unprecedented amounts of capital in 2019. Our April Feature looked at Europe’s biotech renaissance and asks if they can survive what are likely to be leaner times ahead #NBTBestof2020 https://t.co/Y4VuWmDtoB https://t.co/u
[Paper] Europe’s biotech renaissance(@NatureBiotech) https://t.co/JG8d9OJa2r "Nasdaq as the public market of choice for EU biotechs" "Top eight EU biotech IPOs were on Nasdaq" "Startups in novel, fast-moving fields need Nasdaq to raise money fast enough to
RT @NatureBiotech: Europe’s biotech renaissance. European biotech companies continued to raise unprecedented amounts of capital last year.…
RT @pigiparacchi: @GenentaScience on @NatureBiotech https://t.co/85WsSXB1RV Several experts predict that Europe’s biotechs may benefit fro…
RT @pigiparacchi: @GenentaScience on @NatureBiotech https://t.co/85WsSXB1RV Several experts predict that Europe’s biotechs may benefit fro…
@GenentaScience on @NatureBiotech https://t.co/85WsSXB1RV Several experts predict that Europe’s biotechs may benefit from the United States–China standoff @AssobiotecNews @Assolombarda @Italia_Startup @alearesu Genenta raised a series C round from Shangha
“European #biotech companies continued to raise unprecedented amounts of capital last year. Can they survive what are likely to be leaner times ahead? ” https://t.co/GPXx1g9hXF
#Europe’s biotech renaissance https://t.co/hM6aZ9DcFi
“Europe’s lack of specialist, long-term investors is in part down to the lack of role models. Europe has produced very few fully integrated, revenue-generating biotechs” https://t.co/TC9xAQIhbg
RT @Siftedeu: Last year was a big year for life science startups in Europe, with a record-breaking raise of $3.3 bn. But can they survive w…
Last year was a big year for life science startups in Europe, with a record-breaking raise of $3.3 bn. But can they survive what are likely to be leaner times ahead? #biotech #Europe https://t.co/qXn49c3ila https://t.co/SAvUvqBCZ6
RT @levshapiro: Europe’s biotech renaissance. European biotech companies raised unprecedented amounts of capital last year. Can they surviv…
Europe’s biotech renaissance. European biotech companies raised unprecedented amounts of capital last year. Can they survive leaner times ahead? @NatureBiotech @Nature @RealEndptsMel https://t.co/qJoj1L0UeD #EUbiotech #biopharma #healthtechnology https://t
RT @ATCGPartners: In 2019, #EuropeanBiotechs raised unprecedented amounts of capital @RealEndptsMel underlines: “if drugs against #COVID19…
RT @ATCGPartners: In 2019, #EuropeanBiotechs raised unprecedented amounts of capital @RealEndptsMel underlines: “if drugs against #COVID19…
In 2019, #EuropeanBiotechs raised unprecedented amounts of capital @RealEndptsMel underlines: “if drugs against #COVID19 do emerge, 2020 may also be the year that they remind the wider world, not just investors, of the value it can deliver” @NatureBiotech
https://t.co/Ui3c4jBkHK Europe’s #biotech renaissance by Melanie Senior
RT @NatureBiotech: The European biotech industry’s macro-drivers, unmet need, continue to be strong—perhaps even more so during what is bil…
Europe’s #biotech renaissance: "expanding #fund sizes among existing #venturecapital companies and interest in biotech from new kinds of #investors, including #privateequity, sovereign #wealthfunds and #familyoffices" https://t.co/TiyzeVxH1a @NatureBiotech
RT @AkosNyerges: Europe’s (pre #COVID19... ) biotech renaissance @NatureBiotech https://t.co/9GxGgtgvJ9 Will 2020 remind us of the valu…
RT @Magda_Skipper: European #biotech companies continued to raise unprecedented amounts of capital last year. Can they survive what are lik…
RT @Magda_Skipper: European #biotech companies continued to raise unprecedented amounts of capital last year. Can they survive what are lik…
RT @Magda_Skipper: European #biotech companies continued to raise unprecedented amounts of capital last year. Can they survive what are lik…
Europe’s (pre #COVID19... ) biotech renaissance @NatureBiotech https://t.co/9GxGgtgvJ9 Will 2020 remind us of the value that #Bio hold? https://t.co/Ss5ATq65a2
RT @NatureBiotech: The European biotech industry’s macro-drivers, unmet need, continue to be strong—perhaps even more so during what is bil…
RT @NatureBiotech: The European biotech industry’s macro-drivers, unmet need, continue to be strong—perhaps even more so during what is bil…
RT @NatureBiotech: The European biotech industry’s macro-drivers, unmet need, continue to be strong—perhaps even more so during what is bil…
RT @NatureBiotech: The European biotech industry’s macro-drivers, unmet need, continue to be strong—perhaps even more so during what is bil…
RT @NatureBiotech: The European biotech industry’s macro-drivers, unmet need, continue to be strong—perhaps even more so during what is bil…
The European biotech industry’s macro-drivers, unmet need, continue to be strong—perhaps even more so during what is billed as the worst pandemic in a century https://t.co/mEnLrIHEP0 #COVID19 https://t.co/15tL95XTFo
RT @NatureBiotech: Europe’s biotech renaissance. European biotech companies continued to raise unprecedented amounts of capital last year.…
RT @NatureBiotech: Europe’s biotech renaissance. European biotech companies continued to raise unprecedented amounts of capital last year.…
RT @NatureBiotech: Europe’s biotech renaissance. European biotech companies continued to raise unprecedented amounts of capital last year.…
RT @NatureBiotech: Europe’s biotech renaissance. European biotech companies continued to raise unprecedented amounts of capital last year.…
RT @NatureBiotech: Europe’s biotech renaissance. European biotech companies continued to raise unprecedented amounts of capital last year.…
RT @NatureBiotech: Europe’s biotech renaissance. European biotech companies continued to raise unprecedented amounts of capital last year.…
RT @NatureBiotech: Europe’s biotech renaissance. European biotech companies continued to raise unprecedented amounts of capital last year.…
RT @NatureBiotech: Europe’s biotech renaissance. European biotech companies continued to raise unprecedented amounts of capital last year.…
RT @NatureBiotech: Europe’s biotech renaissance. European biotech companies continued to raise unprecedented amounts of capital last year.…
RT @NatureBiotech: Europe’s biotech renaissance. European biotech companies continued to raise unprecedented amounts of capital last year.…
RT @NatureBiotech: Europe’s biotech renaissance. European biotech companies continued to raise unprecedented amounts of capital last year.…
RT @NatureBiotech: Europe’s biotech renaissance. European biotech companies continued to raise unprecedented amounts of capital last year.…
RT @NatureBiotech: Europe’s biotech renaissance. European biotech companies continued to raise unprecedented amounts of capital last year.…
RT @NatureBiotech: Europe’s biotech renaissance. European biotech companies continued to raise unprecedented amounts of capital last year.…
Europe’s biotech renaissance. European biotech companies continued to raise unprecedented amounts of capital last year. Can they survive what are likely to be leaner times ahead? https://t.co/Y4VuWmDtoB https://t.co/xrh37NibHH
European #biotech companies continued to raise unprecedented amounts of capital last year. Can they survive what are likely to be leaner times ahead? https://t.co/k4InzuPDVh
“Europe’s #biotech renaissance” via @nature https://t.co/6VPdcVHst3
RT @bio_futures: European biotech companies continued to raise unprecedented amounts of capital last year. Can they survive what are likely…
RT @bio_futures: European biotech companies continued to raise unprecedented amounts of capital last year. Can they survive what are likely…
European biotech companies continued to raise unprecedented amounts of capital last year. Can they survive what are likely to be leaner times ahead? @nature https://t.co/Q7TYu60Mzb
European #biotech companies continued to raise unprecedented amounts of capital last year. Can they survive what are likely to be leaner times ahead? https://t.co/k4InzuPDVh
RT @Magda_Skipper: European #biotech companies continued to raise unprecedented amounts of capital last year. Can they survive what are lik…
European #biotech companies continued to raise unprecedented amounts of capital last year. Can they survive what are likely to be leaner times ahead? https://t.co/Pwd1296JQf
European #biotech companies continued to raise unprecedented amounts of capital last year. Can they survive what are likely to be leaner times ahead? @NatureBiotech https://t.co/LlKFNVFp94 https://t.co/R9xa30xlNV